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1230temperature was infused at 20 ml/min through the
RayFlow catheter to measure hyperemic absolute
flow (4,5). Under this steady state hyperemia, the
balloon catheter was slowly inflated to obtain a
graded, controlled stenosis. Figure 1A shows the
simultaneously recorded aortic and distal coronary
pressures and thermodilution-derived proximal LAD
flow (QS) during steady state maximal hyperemia.
Figure 1B shows the corresponding hyperemic
pressure-flow relationship. Aortic and distal coronary
pressures were corrected for a coronary wedge pres-
sure of 20 mm Hg (Pw, measured but not displayed).
This relationship is linear, and its intercept is close to
zero (y ¼ 0.87x þ 0.04; R ¼ 0.99 [95% confidence
interval: 0.98 to 0.99]; p < 0.001).
These results confirm earlier animal data and
demonstrate the linearity of the hyperemic pressure/
flow relationship during hyperemia in humans, thus
confirming the theoretical background of FFR
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Reactivity in PatientsWith
Atrial FibrillationAtrial fibrillation (AF) is the most common sustained
cardiac rhythm abnormality and is associated with
substantial risk of stroke and thromboembolism,
leading to low quality of life and high mortality. Pa-
tients with AF are at heightened risk of cognitive
decline and dementia, even in the absence of a
medical history of past stroke (1). One factor that
potentially contributes to these complications is an
impairment in cerebrovascular reactivity. The cere-
bral vasculature is very sensitive to changes in arte-
rial carbon dioxide (CO2). Cerebrovascular CO2
reactivity (CVRCO2) is impaired in several neurode-
generative disorders, and independently predicts the
occurrence of ischemic stroke (2) and cardiovascular
mortality. We aimed to test the hypothesis that
CVRCO2 is reduced in AF.
CVRCO2 was determined in patients with AF (n ¼ 31;
median age 69 years [interquartile range (IQR): 64 to
72 years]), patients with hypertension (n ¼ 31; median
age 68 years [IQR: 65 to 72 years]), and healthy con-
trol subjects (n ¼ 30; median age 69 years [IQR: 66 to
73 years]) from the slope of the change in middle
cerebral artery mean blood flow velocity (MCAvmean)
(transcranial Doppler ultrasound) versus end-tidal
CO2 partial pressure (PETCO2) between 2 4-min hy-
percapnic steps of 4% and 7% CO2 (w21% oxygen,
nitrogen balanced) delivered via the open circuit
steady-state method (3). AF patients had a diagnosis
of paroxysmal or persistent AF, while hypertensive
patients were also clinically diagnosed (i.e., consis-
tent nonclinical ambulatory blood pressure of systolic
>140 mm Hg and/or diastolic >90 mm Hg). Patients
with hypertension served as a “disease control”
group to account for the effect of medications and
comorbidities. All procedures performed were
approved by the National Research Ethics Service
Committee West Midlands (13/WM/0210 and 15/WM/
0447) and conformed to the Declaration of Helsinki
(2008).
CVRCO2 wasw31% lower in patients with AF versus
healthy control subjects and patients with hyperten-
sion (p < 0.001) (Figure 1A). Systemic endothelial
dysfunction (increased plasma von Willebrand factor,
FIGURE 1 CVRCO2 in HC, in Patients With AF and HT, and in AF Subgroups
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Cerebrovascular carbon dioxide reactivity (CVRCO2) in healthy controls (HC) and in patients with atrial fibrillation (AF) and hypertension (HT)
(left), along with AF subgroups (right). Horizontal bars show mean and SD. *p < 0.05 versus HC and HT.
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1231reduced nitrite/nitrate product, and impaired
brachial artery flow-mediated dilatation) has been
reported in AF, possibly due to the irregular heart
rhythm causing alterations in shear stress pattern (4),
and may account for the diminished CVRCO2
observed. Cerebral perfusion, (i.e., MCAvmean) was
w16% lower in patients with AF (mean 51.0 
12.9 cm$s1) and w13% lower in patients with hyper-
tension (53.1  11.1 cm$s1) when compared with
healthy control subjects (60.9  12.9 cm$s1)
(p ¼ 0.006). AF patients who were fibrillating when
studied (55% of total) had a lower MCAvmean (31.1 
8.7 cm$s1) than those not fibrillating (59.2 
10.5 cm$s1) (p < 0.001). Low cerebral perfusion can
lead to vasodilatation of cerebral arterioles, thus
reducing vasodilatory reserve and interfering with
cerebral autoregulation. However, CVRCO2 was not
different between AF subgroups (p ¼ 0.303)
(Figure 1B), suggesting that baseline cerebral perfu-
sion per se was not a major determinant of the
blunted CVRCO2 response, pointing to another shared
factor (e.g., endothelial dysfunction).
CVRCO2 was not different in hypertensive and
normotensive patients, in agreement with some,
but not all, previous studies. These inconsistent
findings may be attributable to differences in patient
characteristics (medications, hypertension etiology,
and severity) and the methodological approach uti-
lized. A variety of approaches have been developed
to determine CVRCO2 and the relative merits are
debated (5). CVRCO2 and MCAvmean showed a goodbetween-day test-retest reliability (intraclass corre-
lation of 0.938; 95% confidence interval [CI]: 0.759
to 0.985; p < 0.001; and 0.981; 95% CI: 0.923 to
0.995; p < 0.001; coefficient of variation for the
method error of 6.06% and 2.95%, respectively),
and CVRCO2 demonstrated an area under the
receiver operating characteristic curve of 0.78 (95%
CI: 0.66 to 0.89).
In summary, AF patients had a lower cerebral
perfusion and impaired CVRCO2 when compared with
healthy control subjects. A poor CVRCO2, indicative of
a limited cerebral vascular reserve, may serve as an
“early warning” of cerebrovascular dysfunction
and worsen stroke outcome in AF by further
compromising the cerebral circulation, increasing
infarction size, and delaying functional recovery after
ischemia. AF patients that were fibrillating when
examined had a worse cerebral perfusion than those
who were not. Low cerebral perfusion is associated
with white matter damage and lower cognitive
test scores. Collectively, our observations may have
implications for AF-related cognitive decline, cere-
brovascular events, and mortality, and require
further exploration.Rehan T. Junejo, PhD
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SCD RiskNo Easy ExplanationsI read with interest the recent paper by Deo et al. (1),
which investigated differences in sudden cardiac
death (SCD) risk between blacks and whites. The
authors demonstrate that in a large cohort, after
hierarchical adjustment for a number of risk factors,
blacks have a 2-fold higher risk of SCD than whites.
I was dismayed, however, to read their conclusion
that “racial differences in the underlying pathophys-
iology of SCD” may explain this difference in risk,
which persists even “after controlling for socio-
demographic and cardiovascular risk factors.” The
implication is that blacks may possess an “underlying
susceptibility to fatal arrhythmias” (1).Our understanding of human genetics does
not support this notion. Race is a complex, socially-
constructed phenomenon encompassing an in-
dividual’s experience across the life course. It is not
based in any essential quality specific to 1 group (2).
Even in those cases where black ancestry-related
gene variants have been associated with disease
(e.g., APOL1, where certain variants are over-
represented among persons of African descent),
their absolute contribution to excess mortality is
small (3).
The authors do acknowledge the possibility of re-
sidual confounding, especially relating to covariates
of education and income. Education and income
variables, as they are often interpreted in published
health disparities data, are at best weak proxies for
what they purport to measure—in the case of blacks in
the United States, the sequelae of historically rooted
structural racism (4).
The authors rightly call for additional research into
racial differences in SCD risk. But it is inaccurate to
conjecture that these differences are due to some
underlying racial predisposition. To do so is to elide
the larger-scale, societal causes of black-white health
disparities in the United States while reifying
the pernicious idea that people can be placed into
biologically distinct categories.*Akshay Pendyal, MD
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